Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
- PMID: 22187060
- DOI: 10.1007/s00296-011-2282-3
Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis
Abstract
To define the relationship between serum anti-cyclic citrullinated peptide antibodies (anti-CCP) and disease activity, and to construct a new disease activity index by using anti-CCP in rheumatoid arthritis (RA). One hundred and five RA patients were included. Disease activity based on DAS28-ESR and serum anti-CCP was measured. There was correlation between serum anti-CCP and DAS28-ESR. (R (2) = 0.71, P value < 0.01). New disease activity index was developed by replacing anti-CCP with ESR in DAS28-ESR. There was correlation between new model and DAS28-ESR. (R (2) = 0.91, P value < 0.01) The new composite index best cut-off values corresponding to DAS28-ESR values of 2.6, 3.2, and 5.1 were 3.21, 3.38, and 4.74, respectively. There was agreement between new model and DAS28-ESR for determination of patients in different disease activity categories. (Kappa = 0.71, P value < 0.01). The new disease activity index that applies serum anti-CCP may predict disease activity in RA.
Similar articles
-
Anti-cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound-detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity.Int J Rheum Dis. 2020 Oct;23(10):1337-1343. doi: 10.1111/1756-185X.13933. Epub 2020 Aug 17. Int J Rheum Dis. 2020. PMID: 33460311
-
The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.Clin Dev Immunol. 2005 Sep;12(3):197-202. doi: 10.1080/17402520500233510. Clin Dev Immunol. 2005. PMID: 16295525 Free PMC article.
-
Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.J Rheumatol. 2008 Jun;35(6):1002-8. Epub 2008 Apr 1. J Rheumatol. 2008. PMID: 18398946
-
Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.Clin Exp Immunol. 2015 Nov;182(2):119-31. doi: 10.1111/cei.12677. Epub 2015 Sep 16. Clin Exp Immunol. 2015. PMID: 26149185 Free PMC article.
-
The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors?Drug News Perspect. 2009 Nov;22(9):543-8. doi: 10.1358/dnp.2009.22.9.1416992. Drug News Perspect. 2009. PMID: 20072731 Review.
Cited by
-
Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis.Cureus. 2021 May 29;13(5):e15314. doi: 10.7759/cureus.15314. Cureus. 2021. PMID: 34221763 Free PMC article.
-
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Rheumatol Int. 2016 Aug;36(8):1043-63. doi: 10.1007/s00296-016-3506-3. Epub 2016 Jun 6. Rheumatol Int. 2016. PMID: 27271502 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous